Estrogen Metabolites
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Affect Breast Cancer Risk
HOW HORMONES AFFECT BREAST CANCER RISK Hormones are chemicals made by the body that control how cells and organs work. Estrogen is a female hormone made mainly in the ovaries. It’s important for sexual development and other body functions. From your first monthly period until menopause, estrogen stimulates normal breast cells. A higher lifetime exposure to estrogen may increase breast cancer risk. For example, your risk increases if you start your period at a young age or go through menopause at a later age. Other hormone-related risks are described below. Menopausal hormone therapy Pills Menopausal hormone therapy (MHT) is The U.S. Food and Drug Administration also known as postmenopausal hormone (FDA) recommends women use the lowest therapy and hormone replacement dose that eases symptoms for the shortest therapy. Many women use MHT pills to time needed. relieve hot flashes and other menopausal Any woman currently taking or thinking symptoms. MHT should be used at the Birth control about taking MHT pills should talk with her lowest dose and for the shortest time pills (oral doctor about the risks and benefits. contraceptives) needed to ease menopausal symptoms. Long-term use can increase breast cancer Vaginal creams, suppositories Current or recent use risk and other serious health conditions. and rings of birth control pills There are 2 main types of MHT pills: slightly increases breast Vaginal forms of MHT do not appear to cancer risk. However, estrogen plus progestin and estrogen increase the risk of breast cancer. However, this risk is quite small alone. if you’ve been diagnosed with breast cancer, vaginal estrogen rings and suppositories are because the risk of Estrogen plus progestin MHT breast cancer for most better than vaginal estrogen creams. -
A Guide to Feminizing Hormones – Estrogen
1 | Feminizing Hormones A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone • Progestin: progesterone Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body. -
Alpha-Fetoprotein: the Major High-Affinity Estrogen Binder in Rat
Proc. Natl. Acad. Sci. USA Vol. 73, No. 5, pp. 1452-1456, May 1976 Biochemistry Alpha-fetoprotein: The major high-affinity estrogen binder in rat uterine cytosols (rat alpha-fetoprotein/estrogen receptors) JOSE URIEL, DANIELLE BOUILLON, CLAUDE AUSSEL, AND MICHELLE DUPIERS Institut de Recherches Scientifiques sur le Cancer, Boite Postale No. 8, 94800 Villejuif, France Communicated by Frangois Jacob, February 3, 1976 ABSTRACT Evidence is presented that alpha-fetoprotein nates in hypotonic solutions, whereas in salt concentrations (AFP), a serum globulin, accounts mainly, if not entirely, for above 0.2 M the 4S complex is by far the major binding enti- the high estrogen-binding properties of uterine cytosols from immature rats. By the use of specific immunoadsorbents to ty. AFP and by competitive assays with unlabeled steroids and The relatively high levels of serum AFP in immature rats pure AFP, it has been demonstrated that in hypotonic cyto- prompted us to explore the contribution of AFP to the estro- sols AFP is present partly as free protein with a sedimenta- gen-binding capacity of uterine homogenates. The results tion coefficient of about 4-5 S and partly in association with obtained with specific anti-AFP immunoadsorbents (12, 13) some intracellular constituent(s) to form an 8S estrogen-bind- provided evidence that at low salt concentrations,'AFP ac-' ing entity. The AFP - 8S transformation results in a loss of antigenic reactivity to antibodies against AFP and a signifi- counts for most of the estrogen-binding capacity associated cant change in binding specificity. This change in binding with the 4-5S macromolecular complex. -
Antiestrogenic Action of Dihydrotestosterone in Mouse Breast
Antiestrogenic action of dihydrotestosterone in mouse breast. Competition with estradiol for binding to the estrogen receptor. R W Casey, J D Wilson J Clin Invest. 1984;74(6):2272-2278. https://doi.org/10.1172/JCI111654. Research Article Feminization in men occurs when the effective ratio of androgen to estrogen is lowered. Since sufficient estrogen is produced in normal men to induce breast enlargement in the absence of adequate amounts of circulating androgens, it has been generally assumed that androgens exert an antiestrogenic action to prevent feminization in normal men. We examined the mechanisms of this effect of androgens in the mouse breast. Administration of estradiol via silastic implants to castrated virgin CBA/J female mice results in a doubling in dry weight and DNA content of the breast. The effect of estradiol can be inhibited by implantation of 17 beta-hydroxy-5 alpha-androstan-3-one (dihydrotestosterone), whereas dihydrotestosterone alone had no effect on breast growth. Estradiol administration also enhances the level of progesterone receptor in mouse breast. Within 4 d of castration, the progesterone receptor virtually disappears and estradiol treatment causes a twofold increase above the level in intact animals. Dihydrotestosterone does not compete for binding to the progesterone receptor, but it does inhibit estrogen-mediated increases of progesterone receptor content of breast tissue cytosol from both control mice and mice with X-linked testicular feminization (tfm)/Y. Since tfm/Y mice lack a functional androgen receptor, we conclude that this antiestrogenic action of androgen is not mediated by the androgen receptor. Dihydrotestosterone competes with estradiol for binding to the cytosolic estrogen receptor of mouse breast, […] Find the latest version: https://jci.me/111654/pdf Antiestrogenic Action of Dihydrotestosterone in Mouse Breast Competition with Estradiol for Binding to the Estrogen Receptor Richard W. -
Feminizing Hormone Therapy
FEMINIZING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health April 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical treatment ▪ WPATH criteria -
Estrone-Compound-Pal-011921
ESTRONE COMPOUND What is this medicine? Estrone (es-trohn) E1 Estrone is a hormone derived from yams and may be given to women who no longer produce a sufficient amount on their own. It may be used to reduce menopause symptoms (e.g., hot flashes, vaginal dryness). It may be used to help prevent bone loss. It may also be used for other conditions as determined by your doctor. Compounded Drug Forms: BLA tablet, sublingual tablet, fast-burst sublingual tablet, vaginal tablet, troche, vaginal suppository, cream, gel What should I tell my health care provider before I take this medicine? Allergy to estrone Pregnant or breastfeeding Have undiagnosed severe vaginal bleeding Active cancer of the breast or uterus A history of blood clots, stroke or heart attacks Smoking while using this medication may increase your risk of blood clots. Have liver dysfunction or disease How should I use this medicine? Follow the package directions provided by Belmar Pharmacy and by your prescriber. Your dosage is based on your medical condition and response to therapy. Follow the dosing schedule provided carefully. Oral tablets may be taken with or without food, if it upsets your stomach take it with a small meal. Sublingual tablets and fast-burst sublingual tablets should be placed under the tongue or between the cheek and gums and held in place until fully dissolved. Avoid swallowing saliva to ensure best absorption into the blood stream. Avoid eating or drinking 15 minutes before or after taking sublingual tablet. Topical products can be applied to the inner arm, upper thigh, back of the knee, tops of the feet and inner wrists. -
Degradation and Metabolite Formation of Estrogen Conjugates in an Agricultural Soil
Journal of Pharmaceutical and Biomedical Analysis 145 (2017) 634–640 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis j ournal homepage: www.elsevier.com/locate/jpba Degradation and metabolite formation of estrogen conjugates in an agricultural soil a,b b,∗ Li Ma , Scott R. Yates a Department of Environmental Sciences, University of California, Riverside, CA 92521, United States b Contaminant Fate and Transport Unit, U.S. Salinity Laboratory, Agricultural Research Service, United States Department of Agriculture, Riverside, CA 92507, United States a r t i c l e i n f o a b s t r a c t Article history: Estrogen conjugates are precursors of free estrogens such as 17ß-estradiol (E2) and estrone (E1), which Received 10 April 2017 cause potent endocrine disrupting effects on aquatic organisms. In this study, microcosm laboratory Received in revised form 11 July 2017 ◦ experiments were conducted at 25 C in an agricultural soil to investigate the aerobic degradation and Accepted 31 July 2017 metabolite formation kinetics of 17ß-estradiol-3-glucuronide (E2-3G) and 17ß-estradiol-3-sulfate (E2- Available online 1 August 2017 3S). The aerobic degradation of E2-3G and E2-3S followed first-order kinetics and the degradation rates were inversely related to their initial concentrations. The degradation of E2-3G and E2-3S was extraordi- Keywords: narily rapid with half of mass lost within hours. Considerable quantities of E2-3G (7.68 ng/g) and E2-3S Aerobic degradation 17ß-estradiol-3-glucuronide (4.84 ng/g) were detected at the end of the 20-d experiment, particularly for high initial concentrations. -
The 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer Whereas Resveratrol and N-Acetylcysteine Are the Preventers
International Journal of Molecular Sciences Review The 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer whereas Resveratrol and N-acetylcysteine Are the Preventers Ercole Cavalieri 1 and Eleanor Rogan 2,* 1 Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198-6805, USA; [email protected] 2 Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, 984388 Nebraska Medical Center, Omaha, NE 68198-4388, USA * Correspondence: [email protected] Abstract: This article reviews evidence suggesting that a common mechanism of initiation leads to the development of many prevalent types of cancer. Endogenous estrogens, in the form of catechol estrogen-3,4-quinones, play a central role in this pathway of cancer initiation. The catechol estrogen- 3,4-quinones react with specific purine bases in DNA to form depurinating estrogen-DNA adducts that generate apurinic sites. The apurinic sites can then lead to cancer-causing mutations. The process of cancer initiation has been demonstrated using results from test tube reactions, cultured mammalian cells, and human subjects. Increased amounts of estrogen-DNA adducts are found not only in people with several different types of cancer but also in women at high risk for breast cancer, indicating that the formation of adducts is on the pathway to cancer initiation. Two compounds, resveratrol, and N-acetylcysteine, are particularly good at preventing the formation of estrogen-DNA Citation: Cavalieri, E.; Rogan, E. The adducts in humans and are, thus, potential cancer-prevention compounds. 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer whereas Keywords: cancer initiation; cancer prevention; estrogens; estrogen-DNA adducts; Resveratrol and N-acetylcysteine Are N-acetylcysteine; resveratrol the Preventers. -
VI.2 Elements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology In women in menopausal period, the decrease of hormones (estrogen levels) result in genital areas becoming dry, itchy and more easily irritated. Vaginal atrophy is a frequent complaint of these women. Symptoms associated with vulvovaginal atrophy (VVA), such as lack of lubrication and pain with intercourse, affect 20% to 45% of midlife and older women. About 50% of otherwise healthy women over 60 years of age experience symptoms related to urogenital atrophy such as vaginal dryness, dyspareunia, burning, itching, as well as urinary complaints or infections of the lower urinary tract. As these alterations frequently affect the quality of life of postmenopausal women, it is important for doctors to detect their presence and offer treatment options. VI.2.2 Summary of treatment benefits Estriol normalizes the vaginal, cervical and urethral epithelium and thus helps to restore the normal microflora and the physiological pH in the vagina. Moreover, estriol increases the resistance of the vaginal epithelial cells to infection and inflammation and decreases the incidence of urogenital complaints. Estriol, which is an estrogen, can be used in the treatment of vaginal symptoms and complaints (vaginal dryness, itching, discomfort and painful intercourse) due to estrogen deficiency related to menopause (whether naturally or surgically induced). In a randomized clinical trial versus placebo, intravaginal application of a low dose of estriol (50 micrograms per application) the main endpoint was to evaluate the efficacy of the product by evaluation of the change in the maturation value of the vaginal epithelium after 12 weeks of treatment. -
Total Estradiol and Total Testosterone
Laboratory Procedure Manual Analyte: Total Estradiol and Total Testosterone Matrix: Serum Method: Simultaneous Measurement of Estradiol and Testosterone in Human Serum by ID LC-MS/MS Method No: 1033 Revised: as performed by: Clinical Chemistry Branch Division of Laboratory Sciences National Center for Environmental Health contact: Dr. Hubert W. Vesper Phone: 770-488-4191 Fax: 404-638-5393 Email: [email protected] James Pirkle, M.D., Ph.D. Division of Laboratory Sciences Important Information for Users CDC periodically refines these laboratory methods. It is the responsibility of the user to contact the person listed on the title page of each write-up before using the analytical method to find out whether any changes have been made and what revisions, if any, have been incorporated. Total Estradiol and Total Testosterone NHANES 2015-16 Public Release Data Set Information This document details the Lab Protocol for testing the items listed in the following table for SAS file TST_I: VARIABLE NAME SAS LABEL (and SI units) LBXTST Testosterone, total (nmol/L) LBXEST Estradiol (pg/mL) 1 of 49 Total Estradiol and Total Testosterone NHANES 2015-16 Contents 1 Summary of Test Principle and Clinical Relevance 7 1.1 Intended Use 7 1.2 Clinical and Public Health Relevance 7 1.3 Test Principle 8 2 Safety Precautions 10 2.1 General Safety 10 2.2 Chemical Hazards 10 2.3 Radioactive Hazards 11 2.4 Mechanical Hazards 11 2.5 Waste Disposal 11 2.6 Training 11 3 Computerization and Data-System Management 13 3.1 Software and Knowledge Requirements 13 3.2 Sample Information 13 3.3 Data Maintenance 13 3.4 Information Security 13 4 Preparation for Reagents, Calibration Materials, Control Materials, and All Other Materials; Equipment and Instrumentation. -
Estrogen Pharmacology. I. the Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man
Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man Mark N. Mueller, Attallah Kappas J Clin Invest. 1964;43(10):1905-1914. https://doi.org/10.1172/JCI105064. Research Article Find the latest version: https://jci.me/105064/pdf Journal of Clinical Investigation Vol. 43, No. 10, 1964 Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) inMan* MARK N. MUELLER t AND ATTALLAH KAPPAS + WITH THE TECHNICAL ASSISTANCE OF EVELYN DAMGAARD (From the Department of Medicine and the Argonne Cancer Research Hospital,§ the University of Chicago, Chicago, Ill.) This report 1 describes the influence of natural biological action of natural estrogens in man, fur- estrogens on liver function, with special reference ther substantiate the role of the liver as a site of to sulfobromophthalein (BSP) excretion, in man. action of these hormones (5), and probably ac- Pharmacological amounts of the hormone estradiol count, in part, for the impairment of BSP dis- consistently induced alterations in BSP disposal posal that characterizes pregnancy (6) and the that were shown, through the techniques of neonatal period (7-10). Wheeler and associates (2, 3), to result from profound depression of the hepatic secretory Methods dye. Chro- transport maximum (Tm) for the Steroid solutions were prepared by dissolving crystal- matographic analysis of plasma BSP components line estradiol and estriol in a solvent vehicle containing revealed increased amounts of BSP conjugates 10% N,NDMA (N,N-dimethylacetamide) 3 in propylene during estrogen as compared with control pe- glycol. Estradiol was soluble in a concentration of 100 riods, implying a hormonal effect on cellular proc- mg per ml; estriol, in a concentration of 20 mg per ml. -
Low-Dose Vaginal Estrogen Therapy
where it works locally to improve the quality of the skin by normalizing its acidity and making it thicker and better lu- bricated. The advantage of using local therapy rather than systemic therapy (i.e. hormone tablets or patches, etc.) is that much lower doses of hormone can be used to achieve good effects in the vagina, while minimizing effects on Low-Dose Vaginal other organs such as the breast or uterus. Vaginal estrogen comes in several forms such as vaginal tablet, creams or gel Estrogen Therapy or in a ring pessary. Is local estrogen therapy safe for me? A Guide for Women Vaginal estrogen preparations act locally on the vaginal 1. Why should I use local estrogen? skin, and minimal, if any estrogen is absorbed into the bloodstream. They work in a similar way to hand or face 2. What is intravaginal estrogen therapy? cream. If you have had breast cancer and have persistent 3. Is local estrogen therapy safe for me? troublesome symptoms which aren’t improving with vagi- 4. Which preparation is best for me? nal moisturizers and lubricants, local estrogen treatment 5. If I am already on HRT, do I need local estrogen may be a possibility. Your Urogynecologist will coordinate the use of vaginal estrogen with your Oncologist. Studies so as well? far have not shown an increased risk of cancer recurrence in women using vaginal estrogen who are undergoing treat- ment of breast cancer or those with history of breast cancer. Which preparation is best for me? Your doctor will be able to advise you on this but most women tolerate all forms of topical estrogen.